Boehringer Ingelheim relies on new cancer therapies from Vienna

The Austrian subsidiary of the German pharmaceutical company Boehringer Ingelheim looks back on a successful year 2025. Despite the expiry of the patent protection for an important preparation, sales revenue in the Central and Eastern Europe and Central Asia region served from Vienna increased by 8.6 percent to 1.588 billion euros. The entire group, which develops and produces medicines for people and animals, had sales of 27.8 billion euros. These were sales drivers Diabetes drug Jardiance and the lung drug Ofev. Humanpharma accounts for 80 percent of sales.

Epidemics caused growth in veterinary medicine

In Austria there was a slight increase in sales from 151.4 to 152.2 million euros. While the human pharmaceutical sector declined slightly, there was a strong increase of 14 percent to 23.2 million euros in veterinary medicine. Boehringer benefited from the many animal diseases in Europe, such as bluetongue and foot-and-mouth disease in Kazakhstan. New drugs against bird flu and rabies should bring further growth.

By Editor